NervGen Pharma Corp. (NGEN)
NGENNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$1.39
-0.0050 (-0.36%) today
Regular session, Nov 10, 9:30 AM ET
- Market cap
- $149.59m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $1.39 to $1.39
- 52-week range
- $1.28 to $6.30
- Average volume
- 487.2k
- Previous close
- $1.40
Analysts
2 coveringBuy2 buy, 0 hold, 0 sell
Targets a year out average $10.00, +619.4% from here
Earnings
next estimate $0.0100Next report Nov 12, 2026
Mar 2026
-28.6%
Jun 2026
-311.1%
estimate reported, and the surprise
Financials
| Quarter | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$4.19m | -$4.97m | -$4.26m | -$3.57m |
| Net income | -$2.74m | -$6.82m | -$2.80m | -$19.89m |
News
2 latestThe company
NervGen (NASDAQ: NGEN) is a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. The Company's mission is to transform the lives of individuals living with SCI by enabling the nervous system to repair itself. NervGen's lead therapeutic candidate, NVG-291, is a subcutaneously administered neuroreparative peptide designed to target the inhibitory CSPG-PTP pathway. NVG-291 is the first pharmacologic candidate to improve function, independence, and quality of life in chronic SCI, as observed in the Phase 1b/2a CONNECT SCI study.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- nervgen.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.